Related Experiment Video
Updated: Dec 21, 2025
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
944
Extraprostatic extension in prostate cancer: primer for radiologists
Alice C Shieh1, Ezgi Guler1,2, Vijayanadh Ojili3
1Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Abdominal Radiology (New York)
|May 12, 2020
Summary
Detecting extraprostatic extension (EPE) in prostate cancer is crucial for treatment decisions. Advanced MRI techniques and targeted biopsies improve EPE detection, aiding in accurate risk stratification and patient management.
Area of Science:
- Radiology
- Urology
- Oncology
Background:
- Extraprostatic extension (EPE) on multiparametric MRI (mpMRI) is critical for prostate cancer management.
- EPE predicts biochemical recurrence after radical prostatectomy (RP), influencing treatment strategies like wider margins or adjuvant therapies (RT, ADT).
Purpose of the Study:
- To evaluate the accuracy of current mpMRI staging guidelines (PI-RADS v2) for detecting EPE.
- To explore refined MRI protocols and additional imaging criteria to improve EPE detection and risk stratification in prostate cancer.
Main Methods:
- Analysis of mpMRI data, including PI-RADS v2 guidelines.
- Investigation of indirect imaging criteria: index tumor volume, capsular contact length, and apparent diffusion coefficient (ADC).
- Evaluation of MRI/ultrasound fusion-guided targeted biopsy for EPE detection.
Main Results:
- PI-RADS v2 shows high specificity but limited sensitivity for EPE detection.
- Index tumor volume, capsular contact length, and ADC are independent predictors of EPE.
- Fusion-guided biopsy detects EPE missed by standard biopsy.
Conclusions:
- Current mpMRI protocols and prediction tools require refinement for accurate EPE staging.
- Incorporating additional imaging features and fusion-guided biopsy enhances EPE detection and risk stratification for prostate cancer management.
